Chandra JD - Surface Oncology Dep Property
| SURFDelisted Stock | USD 0.96 0.03 3.23% |
Insider
Chandra JD is Dep Property of Surface Oncology
| Phone | 617 714 4096 |
| Web | https://www.surfaceoncology.com |
Surface Oncology Management Efficiency
The company has return on total asset (ROA) of (0.4142) % which means that it has lost $0.4142 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0578) %, meaning that it created substantial loss on money invested by shareholders. Surface Oncology's management efficiency ratios could be used to measure how well Surface Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Surface Oncology currently holds 56.04 M in liabilities with Debt to Equity (D/E) ratio of 0.45, which is about average as compared to similar companies. Surface Oncology has a current ratio of 8.03, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Surface Oncology's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Igor Bilinsky | Iovance Biotherapeutics | 51 | |
| Howard MBA | Iovance Biotherapeutics | 64 | |
| Friedrich MD | Iovance Biotherapeutics | 57 | |
| Dotan Borenstein | Evogene | N/A | |
| Michael Snyder | Personalis | N/A | |
| Madan Jagasia | Iovance Biotherapeutics | N/A | |
| Nancy MD | Syros Pharmaceuticals | 63 | |
| Esq JD | Iovance Biotherapeutics | 48 | |
| Courtney Solberg | Syros Pharmaceuticals | N/A | |
| Elran MBA | Evogene | 44 | |
| James MD | Syros Pharmaceuticals | 52 | |
| Daniel Durocher | Repare Therapeutics | N/A | |
| JeanMarc MBA | Iovance Biotherapeutics | 52 | |
| Philip Herman | Repare Therapeutics | 44 | |
| Yaron Eldad | Evogene | 59 | |
| Nir Arbel | Evogene | 44 | |
| Jason Haas | Syros Pharmaceuticals | 56 | |
| John West | Personalis | 67 | |
| Frank Sicheri | Repare Therapeutics | N/A | |
| David MD | Syros Pharmaceuticals | 61 | |
| Nathanael Gray | Syros Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.06 | |||
| Return On Asset | -0.41 |
Surface Oncology Leadership Team
Elected by the shareholders, the Surface Oncology's board of directors comprises two types of representatives: Surface Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Surface. The board's role is to monitor Surface Oncology's management team and ensure that shareholders' interests are well served. Surface Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Surface Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shannon Devens, Sr Operations | ||
| Robert MD, CEO Pres | ||
| Vito Palombella, Chief Scientific Officer | ||
| Chandra JD, Dep Property | ||
| Lisa McGrath, Chief Officer | ||
| Henry Rath, Chief Officer | ||
| Alison MD, Chief Officer | ||
| Jessica CPA, CFO Treasurer |
Surface Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Surface Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.06 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 60.82 M | |||
| Shares Owned By Insiders | 7.27 % | |||
| Shares Owned By Institutions | 46.03 % | |||
| Number Of Shares Shorted | 165.27 K | |||
| Price To Earning | 0.64 X | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.60 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |